Huiyuan Qiu1, Xiubing Zhang2, Wenkai Ni1, Weidong Shi2, Hui Fan2, Jian Xu2, Yongmei Chen2, Runzhou Ni3, Tao Tao4. 1. Department of Gastroenterology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, 226001, Jiangsu Province, People's Republic of China. 2. Department of Medical Oncology, Second Peoples Hospital of Nantong, 43 Xinglong Road, Nantong, 226001, Jiangsu Province, People's Republic of China. 3. Department of Gastroenterology, Affiliated Hospital of Nantong University, 20 Xisi Road, Nantong, 226001, Jiangsu Province, People's Republic of China. nrz1234@yeah.net. 4. Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, 19 Qixiu Road, Nantong, 226001, Jiangsu Province, People's Republic of China. tao1234tao@yeah.net.
Abstract
BACKGROUND: Cell division cycle 5-like (Cdc5L), as a pre-mRNA splicing factor, is a regulator of mitotic progression. Previous study found that deletion of endogenous Cdc5L decreases the cell viability via dramatic mitotic arrest, while the role of Cdc5L in cancer biology remains under debate. AIMS: To investigate the involvement of Cdc5L in the progression of hepatocellular carcinoma (HCC). METHODS: In this study, the expression of Cdc5L was evaluated by Western blot in 8 paired fresh HCC tissues and immunohistochemistry on 116 paraffin-embedded slices. We treated HCC cells by nocodazole to analyze the role of Cdc5L in mitotic progress. To determine whether Cdc5L could regulate the proliferation of HCC cells, we increased endogenous Cdc5L and analyzed the proliferation of HCC cells using Western blot, CCK8, flow cytometry assays, and colony formation analyses. Furthermore, Cdc5L-siRNA oligos were used to confirm that Cdc5L plays an essential role in HCC development. RESULTS: Cdc5L was highly expressed in HCC and significantly associated with multiple clinicopathological factors, including AJCC stage, tumor size, and Ki-67. Besides, univariate and multivariate survival analyses demonstrated that high Cdc5L expression was an independent prognostic factor for HCC patients' poor survival. Overexpression of Cdc5L favors cell cycle progress of HCC cells, while downregulation of Cdc5L results in cell cycle arrest at G2/M phase and reduced cell proliferation of HCC cells. CONCLUSIONS: Our findings suggested that Cdc5L could play an important role in the tumorigenesis of HCC and thus be a potential therapeutical target to prevent HCC progression.
BACKGROUND: Cell division cycle 5-like (Cdc5L), as a pre-mRNA splicing factor, is a regulator of mitotic progression. Previous study found that deletion of endogenous Cdc5L decreases the cell viability via dramatic mitotic arrest, while the role of Cdc5L in cancer biology remains under debate. AIMS: To investigate the involvement of Cdc5L in the progression of hepatocellular carcinoma (HCC). METHODS: In this study, the expression of Cdc5L was evaluated by Western blot in 8 paired fresh HCC tissues and immunohistochemistry on 116 paraffin-embedded slices. We treated HCC cells by nocodazole to analyze the role of Cdc5L in mitotic progress. To determine whether Cdc5L could regulate the proliferation of HCC cells, we increased endogenous Cdc5L and analyzed the proliferation of HCC cells using Western blot, CCK8, flow cytometry assays, and colony formation analyses. Furthermore, Cdc5L-siRNA oligos were used to confirm that Cdc5L plays an essential role in HCC development. RESULTS:Cdc5L was highly expressed in HCC and significantly associated with multiple clinicopathological factors, including AJCC stage, tumor size, and Ki-67. Besides, univariate and multivariate survival analyses demonstrated that high Cdc5L expression was an independent prognostic factor for HCC patients' poor survival. Overexpression of Cdc5L favors cell cycle progress of HCC cells, while downregulation of Cdc5L results in cell cycle arrest at G2/M phase and reduced cell proliferation of HCC cells. CONCLUSIONS: Our findings suggested that Cdc5L could play an important role in the tumorigenesis of HCC and thus be a potential therapeutical target to prevent HCC progression.
Authors: Michael Grote; Elmar Wolf; Cindy L Will; Ira Lemm; Dmitry E Agafonov; Adrian Schomburg; Wolfgang Fischle; Henning Urlaub; Reinhard Lührmann Journal: Mol Cell Biol Date: 2010-02-22 Impact factor: 4.272
Authors: C Wan; S Hou; R Ni; L Lv; Z Ding; X Huang; Q Hang; S He; Y Wang; C Cheng; X X Gu; G Xu; A Shen Journal: Oncogene Date: 2013-12-16 Impact factor: 9.867
Authors: Matthias Kreppel; Nilofar-Natalie Amir Manawi; Martin Scheer; Hans-Joachim Nickenig; Daniel Rothamel; Timo Dreiseidler; Uta Drebber; Max Zinser; Joachim E Zöller; Orlando Guntinas-Lichius; Simon Florian Preuss Journal: Head Neck Date: 2014-06-20 Impact factor: 3.147
Authors: Bekim Sadikovic; Paul Thorner; Susan Chilton-Macneill; Jeff W Martin; Nilva K Cervigne; Jeremy Squire; Maria Zielenska Journal: BMC Cancer Date: 2010-05-13 Impact factor: 4.430